Label Changes for:
Sutent (sunitinib malate) Capsules
November 2012
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
November 2012
ADVERSE REACTIONS
Post-Marketing Experience
- necrotizing fasciitis, pyoderma gangrenosum
April 2012
WARNINGS AND PRECAUTIONS
Osteonecrosis of the Jaw (ONJ)
- ONJ has been observed in clinical trials and has been reported in post-marketing experience in patients treated with sunitinib. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease, may increase the risk of osteonecrosis of the jaw.
Tumor Lysis Syndrome (TLS)
- Cases of TLS, some fatal, have been observed in clinical trials and have been reported in post-marketing experience, primarily in patients with RCC or GIST treated with SUTENT. Patients generally at risk of TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and treated as clinically indicated
